EFFECT OF 17-ALPHA-HYDROXYPROGESTERONE 17-N-CAPROATE ON VARIOUS PELVIC MALIGNANCIES.
D019326:17-alpha-Hydroxyprogesterone; D000230:Adenocarcinoma; D000970:Antineoplastic Agents; D002208:Caproates; D002294:Carcinoma, Squamous Cell; D002822:Choriocarcinoma; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones; D008637:Mesenchymoma; D009369:Neoplasms; D010051:Ovarian Neoplasms; D010386:Pelvic Neoplasms; D011247:Pregnancy; D012509:Sarcoma; D002583:Uterine Cervical Neoplasms; D014594:Uterine Neoplasms
D000970:Antineoplastic Agents; D002208:Caproates; D006908:Hydroxyprogesterones; D019326:17-alpha-Hydroxyprogesterone
ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, EPIDERMOID; CERVIX NEOPLASMS; CHORIOCARCINOMA; HYDROXYPROGESTERONE; MESENCHYMOMA; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; SARCOMA; UTERINE NEOPLASMS